KP-10614

• Description :

  KP-10614 is a potent, orally active platelet aggregation inhibitor. KP-10614 inhibits platelet aggregation induced by ADP with IC50 of 1 nM. KP-10614 causes dose-dependent inhibition of ex vivo platelet aggregation in rats. KP-10614 shows antithrombotic effects in various thrombosis models. KP-10614 can be used for thrombotic diseases research[1].

• UNSPSC :

  12352211

• Target :

  Others

• Related Pathways :

  Others

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cardiovascular Disease

• Smiles :

  CCC#CC[C@H](C)[C@H](O)/C=C/[C@@H]1[C@]2([H])[C@@](C[C@H]1O)([H])C=C(C2)/C=C\CCC(O)=O

• Molecular Formula :

  C23H32O4

• Molecular Weight :

  372.50

• References & Citations :

  [1]Kanayama T, et al. Antithrombotic effects of KP-10614, a novel and stable prostacyclin (PGI2) analog. J Pharmacol Exp Ther. 1990 Dec;255 (3) :1210-7.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [130273-99-3]